Here's Why Agios Stock Plummeted More Than 20% on Monday
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
Investor's Business Daily on MSN2d
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug
Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, mitapivat.
verywellhealth3d
When Iron Deficiency Anemia Is Not What It Appears to Be
There are two major types of thalassemia: alpha and beta. Alpha globin and beta globin are the building blocks of hemoglobin. Those with alpha thalassemia don't make enough alpha globin and those with ...
Agios presents results from Phase 3 ENERGIZE-T Study of Mitapivat
Agios Pharmaceuticals (AGIO) presented positive results from the Phase 3 ENERGIZE-T study investigating mitapivat, an oral, small molecule PK ...
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –– ...